The immediate results of combined operations in patients with advanced ovarian cancer: the experience of N. N. Blokhin National Medical research Center of Oncology, Ministry of health of russia

Objective: to analyze intraoperative and postoperative complications in patients who underwent combination surgeries for advanced ovarian cancer.

Materials and methods. This retrospective study included patients that underwent primary or interval cytoreductive combination surgeries for advanced (grade III–IV) ovarian cancer at N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia between 2000 and 2017.

Results. We analyzed medical records of 144 patients with grade III–IV ovarian cancer who underwent combination surgery at some stage of their treatment. Almost two-thirds of patients (64.8 %) had complete or optimal volume of surgery. Intraoperative complications were registered in 7 % of patients (n = 10), while postoperative complications were observed in 38.2 % of cases (n = 55). The postoperative death rate was 0.7 % (n = 1).

Conclusions. Higher frequency of complete and optimal cytoreduction, as well as acceptable level of intra- and postoperative complications confirm the need for combination surgeries in patients with advanced ovarian cancer. Aggressive surgical tactics should be used only in specialized cancer hospitals with the involvement of a multidisciplinary team that includes cancer surgeons and anesthesiologists in order to improve both short-term and long-term treatment outcomes in patients with advanced ovarian cancer.

1. ESGO Ovarian Cancer Surgery Guidelines. European Society of Gynaecological Oncology, 2017. V. 2. Available at: http:// guidelines.esgo.org.

2. Chi D.S., Eisenhauer E.L., Zivanovic O. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114(1):26–31.

3. Peiretti M., Zanagnolo V., Aletti G.D. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119(2):259–64. DOI: 10.1016/j. ygyno.2010.07.032.

4. Harter P., Muallem Z.M., Buhrmann C. et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011;121(3):615–9.

5. Wallace S., Kumar A., Mc Gree M. et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecologic Oncology 2017;145(1):21– 6. DOI: 10.1016/j.ygyno.2017.01.029.

6. Benedetti Panici P., Di Donato V., Fischetti M. et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upperabdominal surgery. Gynecol Oncol 2015;137(3):406–11. DOI: 10.1016/j.ygyno.2015.03.043.

7. Peiretti M., Bristow R.E., Zapardiel I. et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 2012;126(2):220–3. DOI: 10.1016/j.ygyno.2012.04.030.

8. Grimm C., Harter P., Alesina P.F. et al. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol 2017;146(3):498–503. DOI: 10.1016/j. ygyno.2017.06.007.

9. Bartl T., Schwameis R., Stift A. et al. Predictive and prognostic implication of bowel resections during primary cytoreductive surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 2018;28(9):1664–71. DOI: 10.1097/IGC.0000000000001369.